797781.06/WLA 375195-00001/4-22-19/ejs/ejs SUNSET & PCH [Aadi Bioscience, Inc.] SUNSET & PCH OFFICE LEASE This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is...Office Lease • March 29th, 2023 • Aadi Bioscience, Inc. • Pharmaceutical preparations • California
AADI BIOSCIENCE, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 29th, 2023 • Aadi Bioscience, Inc. • Pharmaceutical preparations • New Jersey
This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of November 8, 2022 by and between Aadi Bioscience, Inc. (“Aadi”), and Brendan Delaney (“Executive”). This Agreement will be effective January 1, 2023 (the “Effective Date”) and amends and restates the Employment Agreement by and between the Executive and the Company, dated September 14, 2021 (the “Prior Agreement”). Aadi, together with any other subsidiaries, including the entity employing you, shall be referred to in this letter as the “Company”.
AADI BIOSCIENCE, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 29th, 2023 • Aadi Bioscience, Inc. • Pharmaceutical preparations • California
This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of November 8, 2022 by and between Aadi Bioscience, Inc. (“Aadi”), and Neil Desai, Ph.D. (“Executive”). This Agreement will be effective as of January 1, 2023 (the “Effective Date”) except as otherwise expressly provided herein and amends and restates the Employment Agreement by and between the Executive and the Company, dated August 23, 2021 (the “Prior Agreement”). Aadi, together with any other subsidiaries and their respective successors, including the entity employing you, shall be referred to in this letter as the “Company.”
AMENDMENT 01 to NEGOTIATED PURCHASE ORDER TERMS AND CONDITIONS FOR CLINICAL AND COMMERCIAL PRODUCTNegotiated Purchase Order Terms and Conditions • March 29th, 2023 • Aadi Bioscience, Inc. • Pharmaceutical preparations
This Amendment No. 01 to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product of January 13, 2022 (the “Amendment”) is made effective as of August 1, 2022 (“Amendment Effective Date”) by and between Fresenius Kabi, LLC, a Delaware company having a principal place of business at Three Corporate Drive, Lake Zurich, IL 60047 (“FRESENIUS KABI”), and AADi Bioscience, Inc., a Delaware corporation having a principal address at 17383 Sunset Blvd., Suite A 250, Pacific Palisades, CA 90272 (“AADI” or “Customer”). AADI and the Company may hereafter be referred to collectively as the “Parties” and individually as a “Party”.
